Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Phase 1/2 Completed 100 enrolled Beni-Suef University

NaSingle-groupOpen-labelTreatment

Summary

The objective of the investigators was to delineate the efficacy and safety of Ombitasvir, paritaprevir with ritonavir (OBV/PTV/r) plus ribavirin (RBV) on chronic HCV GT4 Egyptian naïve patients

Timeline

Start: 2017-01-05
Primary completion: 2017-09-08
Completion: 2017-09-08

Publications

Background Abdel-Moneim A, Aboud A, Abdel-Gabbar M, Zanaty M, Ramadan M. Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients. Dig Dis Sci. 2018 May;63(5):1341-1347. doi: 10.1007/s10620-018-5005-8. Epub 2018 Mar 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ribavirin	Small molecule	—	Oral
Subject	ombitasvir	Small molecule	—	Oral
Subject	paritaprevir	Small molecule	—	Oral
Background	Ritonavir	Other / unclassified	—	Oral

Ombitasvir /Paritaprevir/Ritonavir Plus Ribavirin on HCV GT4

Summary

Timeline

Publications

Drugs

Indications